Baker Christine D. 4

4 · TYME TECHNOLOGIES, INC. · Filed Sep 16, 2022

Form 4

Period: 2022-09-16

Director

Transactions

Disposition to Issuer
Director Stock Option - Option to buy
2022-09-16−14,666→ 0 total
Exercise: $0.35Exp: 2032-03-22→ Common Stock (14,666 underlying)
Disposition to Issuer
Director Stock Option - Option to buy
2022-09-16−88,000→ 0 total
Exercise: $0.31Exp: 2032-08-23→ Common Stock (36,888 underlying)
Disposition to Issuer
Director Stock Option - Option to buy
2022-09-16−36,888→ 0 total
Exercise: $0.35Exp: 2032-03-22→ Common Stock (36,888 underlying)

Footnotes (3)

[F1]This award consisted of options to purchase 176,000 shares of Tyme common stock, 14,666 of which had vested as of the date of the merger between the issuer and Syros Pharmaceuticals, Inc ("Syros"). The vested portion was assumed by Syros in the merger and replaced with an option to purchase 642 shares of Syros common stock for $7.99 per share, after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split"). The remaining unvested portion of the option award was cancelled upon the reporting person's resignation from the board in connection with the merger, pursuant to the terms of the award.
[F2]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 1,616 shares of Syros common stock for $7.99 per share, after giving effect to the Reverse Split.
[F3]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $7.07 per share, after giving effect to the Reverse Split.

Documents

1 file